The real-world effectiveness of the respiratory syncytial virus (RSV) vaccination among U.S. adults aged 60 years and older during the 2023–2024 RSV season was found to be 75.1% (95% confidence interval, 73.6–76.4%), according to research published in JAMA Network Open. Vaccine effectiveness was evaluated against acute respiratory infection, urgent care or emergency department visits, and hospitalizations. Among those 60 years and younger, the vaccine was 75.8% effective (73.2-78.1%) against urgent care or emergency department visits …
Read More